Volpara Health Technologies Ltd
ASX:VHT
Intrinsic Value
Volpara Health Technologies Ltd. engages in selling the VolparaEnterprise software, which is a cloud-based breast imaging analytics product. [ Read More ]
The intrinsic value of one
VHT
stock under the Base Case scenario is
0.66
AUD.
Compared to the current market price of 1.14 AUD,
Volpara Health Technologies Ltd
is
Overvalued by 42%.
Volpara Health Technologies Ltd's market capitalization is 290m AUD.
VHT stock price is 1.14 AUD.
VHT stock (0.66 AUD) is 42% less than its price (1.14 AUD).
VHT has downside potential of 6% compared to the average analyst price target.
Open Wall St Estimates
VHT's Revenue has grown by an exceptional 24% over the past 12 months.
VHT's short-term liabilties (32m NZD) exceed its short-term assets (28m NZD).
VHT's ROE (Return on Equity) has significantly increased in the last 3 years from -28% to -17%, and is approaching profitability.
VHT's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
VHT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -36% to -13%, and is approaching profitability.
VHT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -13%.
VHT's ROE (Return on Equity) for the past 12 months is negative and is equal to -17%.
VHT's Revenue has been growing by an exceptional 36% per year for the last 3 years.
VHT has negative Operating Income for the last twelve months.
VHT has negative Net Income for the last twelve months.
VHT's long-term assets (80m NZD) exceed its long-term liabilties (32m NZD).
VHT has positive Gross Profit for the last twelve months.
VHT has positive Free Cash Flow for the last twelve months.
VHT's Altman Z-Score is very low and is equal to 0.87.
VHT's D/E (Debt to Equity) is very low and is equal to 0.02.
VHT has negative three-year average ROE (Return on Equity): -23%. The company is not efficient at transforming stockholders' equity into net income.
VHT has negative three-year average ROIC (Return on Invested Capital): -32%. The company is not efficient at using invested capital to generate operating income.
VHT has negative Net Debt. This means that the company has more cash and short-term investments (13m NZD) than debt (800k NZD).
Valuation Backtest
Volpara Health Technologies Ltd
Run backtest to discover the historical profit from buying and selling
VHT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Volpara Health Technologies Ltd
Balance Sheet Decomposition
Volpara Health Technologies Ltd
| Current Assets | 27.7m |
| Cash & Short-Term Investments | 13.2m |
| Receivables | 11.5m |
| Other Current Assets | 3m |
| Non-Current Assets | 52.4m |
| PP&E | 1.5m |
| Intangibles | 46.4m |
| Other Non-Current Assets | 4.5m |
| Current Liabilities | 31.5m |
| Accounts Payable | 5.3m |
| Other Current Liabilities | 26.2m |
| Non-Current Liabilities | 700k |
| Long-Term Debt | 800k |
| Other Non-Current Liabilities | -100k |
Earnings Waterfall
Volpara Health Technologies Ltd
|
Revenue
|
38m
NZD
|
|
Cost of Revenue
|
-2.9m
NZD
|
|
Gross Profit
|
35m
NZD
|
|
Operating Expenses
|
-45.2m
NZD
|
|
Operating Income
|
-10.2m
NZD
|
|
Other Expenses
|
1.3m
NZD
|
|
Net Income
|
-8.9m
NZD
|
Free Cash Flow Analysis
Volpara Health Technologies Ltd
What is Free Cash Flow?
VHT Profitability Score
Profitability Due Diligence
Volpara Health Technologies Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Volpara Health Technologies Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
VHT Solvency Score
Solvency Due Diligence
Volpara Health Technologies Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Volpara Health Technologies Ltd's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VHT Price Targets Summary
Volpara Health Technologies Ltd
According to Wall Street analysts, the average 1-year price target for
VHT
is 1.07 AUD
with a low forecast of 0.76 AUD and a high forecast of 1.3 AUD.
Shareholder Return
VHT Price
Volpara Health Technologies Ltd
| Average Annual Return | -23.02% |
| Standard Deviation of Annual Returns | 21.77% |
| Max Drawdown | -81% |
| Market Capitalization | 290m AUD |
| Shares Outstanding | 254 374 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Volpara Health Technologies Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Volpara Health Technologies Ltd. engages in selling the VolparaEnterprise software, which is a cloud-based breast imaging analytics product. The firm is engaged in developing digital health solutions to enable personalized breast cancer screening based on objective measurements of breast density, compression, and radiation dose. Its geographic segments include North America, Europe, the Middle East and Africa (EMEA), Asia-Pacific (APAC), and Corporate. The firm's offerings include VolparaEnterprise, which enables breast imaging providers to perform control checks; VolparaDensity, which provides objective assessment of a woman's breast density; VolparaRisk is a software that features a patient questionnaire; VolparaLive provides technologists with real-time decision support at the point of care to assess image quality, and Aspen Brest, which is a workflow software that optimizes operations and administration for breast cancer screening programs.
Contact
IPO
Employees
Officers
The intrinsic value of one
VHT
stock under the Base Case scenario is
0.66
AUD.
Compared to the current market price of 1.14 AUD,
Volpara Health Technologies Ltd
is
Overvalued by 42%.
You don't have any saved screeners yet
